<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Annals of Clinical and Experimental Neurology</journal-id><journal-title-group><journal-title xml:lang="en">Annals of Clinical and Experimental Neurology</journal-title><trans-title-group xml:lang="ru"><trans-title>Анналы клинической и экспериментальной неврологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-5473</issn><issn publication-format="electronic">2409-2533</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">746</article-id><article-id pub-id-type="doi">10.25692/ACEN.2021.2.6</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Unknown</subject></subj-group></article-categories><title-group><article-title xml:lang="en">The relationship between the location of a lesion in the striatal dopaminergic innervation and its behavioral manifestation in a 6-hydroxydopamine-induced model of Parkinson's disease in rats</article-title><trans-title-group xml:lang="ru"><trans-title>Взаимосвязь локализации повреждений дофаминовой иннервации стриатума и их поведенческих проявлений на 6-гидроксидофамин-индуцированной модели паркинсонизма у крыс</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Stavrovskaya</surname><given-names>Alla V.</given-names></name><name xml:lang="ru"><surname>Ставровская</surname><given-names>Алла Вадимовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>alla_stav@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Voronkov</surname><given-names>Dmitry N.</given-names></name><name xml:lang="ru"><surname>Воронков</surname><given-names>Дмитрий Николаевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>alla_stav@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Olshansky</surname><given-names>Artem S.</given-names></name><name xml:lang="ru"><surname>Ольшанский</surname><given-names>Артем Сергеевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>alla_stav@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Gushchina</surname><given-names>Anastasia S.</given-names></name><name xml:lang="ru"><surname>Гущина</surname><given-names>Анастасия Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>alla_stav@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Yamshikova</surname><given-names>Nina G.</given-names></name><name xml:lang="ru"><surname>Ямщикова</surname><given-names>Нина Гавриловна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>alla_stav@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Research Center of Neurology</institution></aff><aff><institution xml:lang="ru">ФГБНУ «Научный центр неврологии»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2021-06-17" publication-format="electronic"><day>17</day><month>06</month><year>2021</year></pub-date><volume>15</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>42</fpage><lpage>49</lpage><history><date date-type="received" iso-8601-date="2021-06-16"><day>16</day><month>06</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2021, Stavrovskaya A.V., Voronkov D.N., Olshansky A.S., Gushchina A.S., Yamshikova N.G.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2021, Stavrovskaya A.V., Voronkov D.N., Olshansky A.S., Gushchina A.S., Yamshikova N.G.</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="en">Stavrovskaya A.V., Voronkov D.N., Olshansky A.S., Gushchina A.S., Yamshikova N.G.</copyright-holder><copyright-holder xml:lang="ru">Stavrovskaya A.V., Voronkov D.N., Olshansky A.S., Gushchina A.S., Yamshikova N.G.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://annaly-nevrologii.com/pathID/article/view/746">https://annaly-nevrologii.com/pathID/article/view/746</self-uri><abstract xml:lang="en"><p><bold>Introduction.</bold> Animal modelling of Parkinson’s disease is an essential step in studying disease pathogenesis and searching for effective treatment methods. An accurate assessment of the resulting model is critical.</p> <p>The <bold>aim </bold>of the study was to identify the correlation between the location of a lesion in the striatal dopaminergic innervation when the neurotoxin 6-hydroxydopamine (6-OHDA) was administered to rodents and the resulting behavior.</p> <p><bold>Materials and methods.</bold> The study was carried out on 75 male Wistar rats that received intranigral injection of 3 µl of 6-OHDA at a dose of 4 µg/µl. The animals were examined in the open field test and narrowing beam walking test 33 days after administration, after which some of the animals were decapitated (<italic>n</italic> = 25) for immunohistochemical analysis.</p> <p><bold>Results.</bold> The inactive animal group was statistically significantly different from the active animal group, with more pronounced damage to the dopamine endings in the dorsomedial (<italic>p</italic> = 0.0235) and ventral (<italic>p</italic> = 0.091) striatum. In contrast, in the active animals, the lesion was primarily in the dorsolateral striatum. In the inactive animal group, the mean distance travelled in the open field test was significantly shorter (<italic>p</italic> &lt; 0.001), while freezing time (<italic>p</italic> &lt; 0.0168) and the average score on the neuroticism scale (<italic>p</italic> &lt; 0.001) were higher compared to the active animals. Spearman's correlation results showed a significant negative correlation (<italic>r<sub>S</sub></italic> = –0.762; <italic>p</italic> &lt; 0.0001) between tyrosine hydroxylase staining intensity in the dorsolateral striatum and freezing time in the open field test. No correlation was found between freezing time and damage to other striatal areas.</p> <p><bold>Conclusion.</bold> Damage to the dorsomedial and dorsolateral striatum causes less severe motor and emotional disturbances than damage to the ventral striatum. The narrowing beam walking test can be used to assess the presence and severity of striatal damage reliably. This evaluation is critical in studies of subsequent treatment efficacy to reduce Parkinsonian syndrome.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение.</bold> Моделирование болезни Паркинсона на животных является важным этапом в изучении патогенеза заболевания и поиска эффективных методов лечения.</p> <p><bold>Цель </bold>исследования — выявить взаимосвязь локализации повреждений дофаминовой иннервации стриатума мозга при введении грызунам нейротоксина 6-гидроксидофамина (6-ГДА) и их поведенческих проявлений.</p> <p><bold>Материалы и методы.</bold> Работа проведена на 75 крысах-самцах Вистар с интранигральным введением 3 мкл 6-ГДА в дозе 4 мкг/мкл. Через 33 сут после введения животные были обследованы в тестах «открытое поле» и «сужающаяся дорожка», после чего часть животных декапитирована (<italic>n</italic> = 25) для проведения иммуногистохимического анализа.</p> <p><bold>Результаты.</bold> Группа неактивных животных статистически значимо отличалась от активных животных более выраженным повреждением ДА-окончаний в дорсомедиальной (<italic>p</italic> = 0,0235) и вентральной (<italic>p</italic> = 0,091) областях стриатума, тогда как у активных животных повреждение преимущественно локализовалось в дорсолатеральной области. В группе неактивных животных среднее пройденное расстояние в «открытом поле» было значимо меньше (<italic>p</italic> &lt; 0,001), а время замирания (<italic>p</italic> &lt; 0,0168) и средний балл по шкале невротизации (<italic>p</italic> &lt; 0,001) — больше по сравнению с активными. Результаты корреляционного анализа по Спирмену показали значимую негативную связь (<italic>r<sub>S</sub></italic> = –0,762; <italic>p</italic> &lt; 0,0001) между интенсивностью окрашивания на тирозингидроксилазу в дорсолатеральном отделе и длительностью замираний в «открытом поле». Связь между длительностью замираний и повреждением других областей стриатума не выявлена.</p> <p><bold>Заключение.</bold> Повреждение дорсомедиальной и дорсолатеральной областей вызывает двигательные и эмоциональные нарушения меньшей степени тяжести, чем повреждения, затрагивающие и вентральную область стриатума. Поведенческий тест «сужающаяся дорожка» может использоваться для достоверной оценки наличия и степени повреждения стриатума. Такая оценка очень важна в исследованиях эффективности последующих терапевтических воздействий для редукции паркинсонического синдрома.</p></trans-abstract><kwd-group xml:lang="en"><kwd>Parkinson's disease</kwd><kwd>6-hydroxydopamine</kwd><kwd>behavior</kwd><kwd>striatal innervation</kwd><kwd>animal models</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>болезнь Паркинсона</kwd><kwd>6-гидроксидофамин</kwd><kwd>поведение</kwd><kwd>иннервация стриатума</kwd><kwd>модели на животных</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Wirdefeldt K., Adami H.O., Cole P. et al. Epidemiology and etiology of Parkinson’s disease: a review of the evidence. Eur J Epidemiol. 2011; 26(S1): 1–58. DOI: 10.1007/s10654-011-9581-6. PMID: 21626386.</mixed-citation></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Illarioshkin S.N. [Modern view on etiology of Parkinson’s disease]. Nevrologicheskiĭ zhurnal. 2015; 20(4): 4–13. (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Иллариошкин С.Н. Современные представления об этиологии болезни Паркинсона. Неврологический журнал. 2015; 20(4): 4–13.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><mixed-citation>Savitt J.M., Dawson V.L., Dawson T.M. Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest. 2006; 116(7): 1744–1754. DOI: 10.1172/JCI29178. PMID: 16823471.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Chaudhuri K.R., Schapira A.H. Non-motor symphoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009; 8(5): 464–474. DOI: 10.1016/S1474-4422(09)70068-7. PMID: 19375664.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Chung S.J., Yoo H.S., Oh J.S. et al. Effect of striatal dopamine depletion on cognition in de novo Parkinson's disease. Parkinsonism Relat Disord. 2018; 51: 43–48. DOI: 10.1016/j.parkreldis.2018.02.048. PMID: 29526657.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Kübler D., Schroll H., Buchert R., Kuhn A.A. Cognitive performance correlates with the degree of dopaminergic degeneration in the associative part of the striatum in non-demented Parkinson’s patients. J Neural Transm. 2017; 124(9): 1073–1081. DOI: 10.1007/s00702-017-1747-2. PMID: 28643101.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Weintraub D., Newberg A.B., Cary M.S. et al. Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson’s disease. J Nucl Med. 2005; 46(2): 227–232. PMID: 15695780.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Chung S.J., Lee J.J., Ham J.H. et al. Striatal dopamine depletion patterns and early non-motor burden in Parkinsons disease. PLoS One. 2016; 11(8): e0161316. DOI: 10.1371/journal.pone.0161316. PMID: 27529171.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Park S.B., Kwon K.Y., Lee J.Y. et al. Lack of association between dopamine transporter loss and non-motor symptoms in patients with Parkinson’s disease: a detailed PET analysis of 12 striatal subregions. Neurol Sci. 2019; 40: 311–317. DOI: 10.1007/s10072-018-3632-7. PMID: 30415448.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Blandini F., Armentero M.T. Animal models of Parkinson’s disease. FEBS J. 2012; 279: 1156–1166. DOI: 10.1111/j.1742-4658.2012.08491.x. PMID: 22251459.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Schober A. Classic toxin-induced animal models of Parkinson’s disease: 6-OHDA and MPTP. Cell Tissue Res. 2004; 318(1): 215–224. DOI: 10.1007/s00441-004-0938-y. PMID: 15503155.</mixed-citation></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Shtock V.N., Levin O.S. [Clinical syndromological classification of extrapyramidal disorders]. Мoscow, 2014. 112 с. (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Шток В.Н., Левин О.С. Клиническая синдромологическая классификация экстрапирамидных расстройств. М., 2014. 112 с.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><mixed-citation>Branchi I., D'Andrea I., Armida M. et al. Nonmotor symptoms in Parkinson's disease: Investigating early‐phase onset of behavioral dysfunction in the 6‐hydroxydopamine‐lesioned rat model. J Neurosci Res. 2008; 86(9): 2050–2061. DOI: 10.1002/jnr.21642. PMID: 18335518.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Henderson J.M., Watson S., Halliday G.M. et al. Relationships between various behavioural abnormalities and nigrostriatal dopamine depletion in the unilateral 6-OHDA-lesioned rat. Behav Brain Res. 2003; 139: 105–113. DOI: 10.1016/S0166-4328(02)00087-6. PMID: 12642181.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Schleimer S.B., Johnston G.A., Henderson J.M. Novel oral drug administration in an animal model of neuroleptic therapy. J Neurosci Methods. 2005; 146: 159–164. DOI: 10.1016/j.jneumeth.2005.02.004. PMID: 16054505.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Allbutt H., Henderson J. Use of the narrow beam test in the rat, 6-hydroxydopamine model of Parkinson’s disease. J Neurosci Meth. 2007; 159: 195–202. DOI: 10.1016/j.jneumeth.2006.07.006. PMID: 16942799.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Sweis B.M., Bachour S.P., Brekke J.A. et al. A modified beam-walking apparatus for assessment of anxiety in a rodent model of blast traumatic brain injury. Behav Brain Res. 2016; 296: 149–156. DOI: 10.1016/j.bbr.2015.09.015. PMID: 26367471.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates: Hard Cover Edition. Elsevier, 2006. P. 456.</mixed-citation></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">Bolotova V.Ts., Krauz V.A., Shustov E.B. Biological model of experimental neurosis in laboratory animals. Biomeditsina. 2015; 1: 66–80. (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Болотова В.Ц., Крауз В.А., Шустов Е.Б. Биологическая модель экспериментального невроза у лабораторных животных. Биомедицина. 2015; 1: 66–80.</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><mixed-citation>Gerfen C.R., Herkenham M., Thibault J. The neostriatal mosaic: II. Patch- and matrix-directed mesostriatal dopaminergic and non-dopaminergic systems. J. Neurosci. 1987; 7(12): 3915–3934. DOI: 10.1523/JNEUROSCI.07-12-03915.1987. PMID: 2891799.</mixed-citation></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">Karkischenko N.N., Grachev S.V. [A guide to laboratory animals and alternative models in biomedical technology]. Мoscow, 2010. 346 p. (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Каркищенко Н.Н., Грачев С.В. Руководство по лабораторным животным и альтернативным моделям в биомедицинских технологиях. М., 2010. 346 c.</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><mixed-citation>Ungerstedt U., Ljungberg T., Steg G. Behavioral, physiological, and neurochemical changes after 6-hydroxy-dopamine-induced degeneration of the nigrostriatal dopamine neurons. Adv Neurol. 1974; 5: 421–426.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Hwang O. Role of oxidative stress in Parkinson’s disease. Exp Neurobiol. 2013; 22: 11–17. DOI: 10.5607/en.2013.22.1.11. PMID: 23585717.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Hernandez-Baltazar D., Mendoza-Garrido M., Martinez-Fong D. Activation of GSK-3β and caspase-3 occurs in Nigral dopamine neurons during the development of apoptosis activated by a striatal injection of 6-hydroxydopamine. PLoS One. 2013; 8(8): e70951. DOI: 10.1317/journal.pone.0070951. PMID: 23940672.</mixed-citation></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">Hernandez-Baltazar D., Zavala-Flores L.M., Villanueva-Olivo A. The 6-hydroxydopamine model and parkinsonian pathophysiology: novel findings in an older model. Neurologia. 2017; 32(8): 533–539. DOI: 10.1016/j.nrleng.2015.06.019. PMID: 26304655.</mixed-citation><mixed-citation xml:lang="ru">Hernandez-Baltazar D., Zavala-Flores L.M., Villanueva-Olivo A. The 6-hydroxydopamine model and parkinsonian pathophysiology: novel findings in an older model. Neurologia. 2017; 32(8): 533–539. DOI: 10.1016/j.nrleng.2015.06.019. PMID: 26304655.</mixed-citation></citation-alternatives></ref><ref id="B26"><label>26.</label><mixed-citation>Bywood P.T., Johnson S.M. Differential vulnerabilities of substantia nigra catecholamine neurons to excitatory amino acid-induced degeneration in rat midbrain slices. Exp Neurol. 2000; 162(1): 180–188. DOI: 10.1006/exnr.2000.7310. PMID: 10716898.</mixed-citation></ref><ref id="B27"><label>27.</label><citation-alternatives><mixed-citation xml:lang="en">Voronkov D.N., Dikalova Yu.V., Khudoerkov R.M., Yamshchikova N.G. Brain nigrostriatal system changes in rotenone-induced parkinsonism (quantitative immune-morphological study). Annals of clinical and experimental neurology. 2013; 7(2): 34–38. (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Воронков Д.Н., Дикалова Ю.В., Худоерков Р.М., Ямщикова Н.Г. Изменения в нигростриатных образованиях мозга при моделировании паркинсонизма, индуцированного ротеноном (количественное иммуноморфологическое исследование). Анналы клинической и экспериментальной неврологии. 2013; 7(2): 34–38.</mixed-citation></citation-alternatives></ref><ref id="B28"><label>28.</label><mixed-citation>Hunnicutt B.J., Jongbloets B.C., Birdsong W.T. et al. A comprehensive excitatory input map of the striatum reveals novel functional organization. Elife. 2016; 28; 5: e19103. DOI: 10.7554/eLife.19103. PMID: 27892854.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Yin H.H., Knowlton B.J. Contributions of striatal subregions to place and response learning. Learn Mem. 2004; 11(4): 459–463. DOI: 10.1101/lm.81004. PMID: 15286184.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Lex B., Sommer S., Hauber W. The role of dopamine in the dorsomedial striatum in place and response learning. Neuroscience. 2011; 172: 212–218. DOI: 10.1016/j.neuroscience.2010.10.081. PMID: 21056091.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Keiflin R., Janak P.H. Dopamine prediction errors in reward learning and addiction: from theory to neural circuitry. Neuron. 2015; 88: 247–263. DOI: 10.1016/j.neuron.2015.08.037. PMID: 26494275.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Jiang H., Kim H.F. Anatomical inputs from the sensory and value structures to the tail of the rat striatum. Front Neuroanat. 2018; 12: 30. DOI: 10.3389/fnana.2018.00030. PMID: 29773980.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Parker N.F., Cameron C.M., Taliaferro J.P. et al. Reward and choice encoding in terminals of midbrain dopamine neurons depends on striatal target. Nat Neurosci. 2016; 19(6): 845–854. DOI: 10.1038/nn.4287. PMID: 27110917.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Brimblecombe K. The striosome and matrix compartments of the striatum: a path through the labyrynth from neurochemistry toward function. ACS Chemical Neurosci. 2017; 8: 235–242. DOI: 10.1021/acschemneuro.6b00333. PMID: 27977131.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Crittenden R., Graybiel A.M. Disease-associated changes in the striosome and matrix compartments of the dorsal striatum. In: Steiner H., Tseng K.Y. (eds.) Handbook of Behavioral Neuroscience. Elsevier, 2016; 24: 783–802. DOI: 0.1016/B978-0-12-802206-1.00039-8.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Miyamoto Y., Katayama S., Shigematsu N. et al. Striosome-based map of the mouse striatum that is conformable to both cortical afferent topography and uneven distributions of dopamine D1 and D2 receptor-expressing cells. Brain Struct Funct. 2018; 223: 4275–4291. DOI: 10.1007/s00429-018-1749-3. PMID: 30203304.</mixed-citation></ref><ref id="B37"><label>37.</label><citation-alternatives><mixed-citation xml:lang="en">Stavrovskaya A.V., Voronkov D.N., Yamshchikova N.G. et al. Morphochemical evaluation of neurotransplantation outcomes in experimental parkinsonism. Annals of clinical and experimental neurology. 2015; 9(2): 28–32. (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Ставровская А.В., Воронков Д.Н., Ямщикова Н.Г. и др. Морфохимическая оценка результатов нейротрансплантации при экспериментальном паркинсонизме. Анналы клинической и экспериментальной неврологии. 2015; 9(2): 28–32.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
